Latest News and Press Releases
Want to stay updated on the latest news?
-
Pixium Vision announces the drawdown of a further tranche, with a nominal value of €1.5 million, under the financing contract with ESGO Paris, 19 April 2021 – 8.00 p.m. CET – Pixium Vision...
-
Pixium Vision annonce le tirage d’une nouvelle tranche de 1,5 M€ de valeur nominale dans le cadre du contrat de financement avec ESGO Paris, le 19 avril 2021 – 20h00 CET – Pixium Vision (FR0011950641...
-
Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021. Paris, 16 April 2021 – 6:00 p.m. CEST - Pixium Vision...
-
Pixium Vision annonce sa position de trésorerie au 31 mars 2021 et fait le point sur ses activités et sa visibilité financière jusqu’à la fin de l’année 2021. Paris, le 16...
-
Pixium Vision announces first patient successful implantation in Prima System pivotal trial PRIMAvera Study is the last clinical step before seeking market approval in Europe in dry AMDBionic vision...
-
Pixium Vision annonce l’implantation réussie du premier patient de l’étude pivot PRIMAvera du Système Prima Cette étude est la dernière étape clinique avant la demande d’autorisation de mise sur le...
-
Termination of the business combination with Second Sight Medical Products, Inc. Paris, France, April 3, 2021 – Considering the private placement recently announced and closed by Second Sight Medical...
-
Termination of the business combination with Second Sight Medical Products, Inc. Paris, France, April 3, 2021 – Considering the private placement recently announced and closed by Second Sight Medical...
-
Abandon du rapprochement avec Second Sight Medical Products, Inc. Paris, France, 3 avril 2021 – Compte-tenu de l’augmentation de capital réalisée récemment par Second Sight Medical Products, Inc....
-
Data mark a major step forward in treatment of atrophic AMD Results confirm the safety and stability of the Prima System implant over 24-30 months follow-upPrima System pivotal PRIMAvera study ongoing...